Welcome to our dedicated page for Nyxoah SA SEC filings (Ticker: NYXH), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Nyxoah SA filings document the company's foreign-private-issuer reporting for its medical-technology business and the Genio system for obstructive sleep apnea. Form 6-K reports furnish quarterly and annual operating results, press releases, manufacturing-capacity updates, clinical and regulatory disclosures, and information incorporated by reference into registration statements on Form S-8 and Form F-3.
The filing record also covers capital-structure and governance matters, including ordinary-share offerings, underwriting agreements, shareholder voting matters, transparency-related ownership information, material-event reports, and exhibits that describe financing terms and public-company obligations.
CVI Investments, Inc. and Heights Capital Management, Inc. report beneficial ownership of 11,014,861 Ordinary Shares of Nyxoah SA, equal to 9.9% of the class. This position includes 828,803 Shares and additional Shares issuable upon conversion of convertible notes, subject to a 9.99% conversion cap on total beneficial ownership. Based on a company disclosure of 100,072,815 Shares outstanding as of June 30, 2026, Heights Capital, as investment manager to CVI, may exercise shared voting and dispositive power over these Shares, while both parties disclaim beneficial ownership beyond their pecuniary interest.
Nyxoah reported second-quarter and first-half 2026 results, with H1 2026 revenue of €14.0 million, up from €2.4 million a year earlier, as U.S. commercialization of its Genio system accelerated. U.S. revenue grew 22% sequentially in Q2 2026 over Q1 2026 and reached €9.5 million for the first half, alongside €4.6 million from international markets.
Despite higher gross profit of €8.2 million, heavy investment in growth led to a net loss of €48.9 million versus €43.0 million in H1 2025, while basic loss per share improved to €0.976 from €1.149 on a larger share base. Cash and financial assets totaled €97.8 million at June 30, 2026, supported by a Q2 equity raise and additional drawdown under the European Investment Bank term loan, providing liquidity for continued U.S. launch and clinical programs.
Nyxoah filed a Form 6-K combining shareholder transparency updates, capital structure data and strong preliminary second quarter 2026 results. U.S. launch momentum drove expected global net revenue of about €7.7 million, including €5.2 million from the U.S., both growing just over 20% sequentially. The company continued building its commercial footprint, training 55 new surgeons, activating 89 new high-volume accounts to reach 180, and entering Q3 with 427 patients submitted under prior authorization.
Nyxoah highlighted that CMS has proposed 2027 reimbursement increases for its Genio procedure, with hospital outpatient payment rising from $31,526 to $35,414 and ASC payment from $27,563 to $31,722. The company also secured $110 million in aggregate financing in Q2 and expects cash, cash equivalents and financial assets of about €97.8 million as of June 30, 2026. Separately, it reported new share count and potential dilution elements and disclosed updated ownership positions, including a 14.55% stake held by entities controlled by Orin Hirchman and a 1.95% stake for ResMed Inc.
ResMed Inc. filed an Amendment No. 2 to a Schedule 13G/A reporting beneficial ownership of 1,943,828 ordinary shares of Nyxoah SA. The filing states this equals 1.95% of Nyxoah's 99,926,284 ordinary shares outstanding as of June 10, 2026. The filing is signed by Aaron Bloomer, Chief Financial Officer.
Nyxoah reported that it received $15 million (€13.8 million) from the second tranche of its loan facility with the European Investment Bank. Together with its recent underwritten equity offering, the company has raised about $110 million in new capital in June 2026.
The non-dilutive EIB debt is intended to fund the U.S. commercial launch of the Genio sleep apnea system, as well as research, development and manufacturing scale-up. Nyxoah also called an extraordinary shareholders’ meeting on July 9, 2026 to renew its authorized capital for up to an amount equal to its current share capital.
The filing further discloses updated ownership positions and threshold crossings for several significant holders, including Robert Taub, Pierre‑Edouard Stérin, Cochlear Limited, Gilde Healthcare and Bank of America Corporation, based on a total of 99,926,284 shares issued as of June 10, 2026.
NYXOAH Schedules beneficial ownership disclosure: AIGH entities and Orin Hirschman report 14,534,880 shares, representing 14.5% of Common Stock. The filing states sole voting and dispositive power over 14,534,880 shares. The filing is jointly made by AIGH Capital Management LLC, AIGH Investment Partners LLC and Mr. Orin Hirschman and is signed with dates shown.
Nyxoah SA filed a Form 6-K to furnish a press release updating investors on its total number of voting rights and shares. The update follows the issuance of 55,232,558 new shares in connection with a previously announced underwritten public offering in the United States.
The offering also included shares sold in a private offering to certain qualified or institutional investors outside the United States, including within the European Union. The press release attached as Exhibit 99.1 is furnished, not filed, under U.S. securities laws.
Cochlear Investments Pty Ltd and Cochlear Limited have updated their ownership disclosure for Nyxoah SA. Cochlear Investments directly holds 5,847,283 Ordinary Shares, which represents 5.91% of Nyxoah’s outstanding Ordinary Shares, based on 98,894,961 shares outstanding as stated in a recent prospectus supplement.
Cochlear Limited, as the parent of Cochlear Investments, may be deemed to indirectly beneficially own the same 5,847,283 shares, with shared voting and dispositive power reported and no sole voting or dispositive power. The filing states that the reporting persons have not conducted any transactions in Nyxoah shares during the past 60 days and do not have rights to acquire additional Ordinary Shares.
Nyxoah entered an underwriting agreement for an underwritten public offering of 55,232,558 ordinary shares at $1.72 (€1.48) per share, with underwriters holding a 30-day option to buy up to 8,284,883 additional shares at the same price, less fees. The deal is expected to generate gross proceeds of about $95 million and net proceeds of approximately $88.5 million (€76.3 million), assuming no exercise of the option, and is expected to close around June 9, 2026 subject to customary conditions. All shares are issued by Nyxoah under its effective Form F-3 shelf, and the company plans to use proceeds to fund U.S. commercialization, Genio system R&D and upgrades, international rollout, clinical research, and general corporate purposes including potential debt repayment and acquisitions. Nyxoah also intends to draw €13.8 million from the second tranche of its European Investment Bank loan in Q2 2026.
Nyxoah is offering 55,232,558 ordinary shares pursuant to a prospectus supplement dated June 5, 2026. The public offering price is €1.48 per share (equivalent to $1.72 per share), with estimated net proceeds of $88.5 million (€76.3 million), and an underwriter option to purchase an additional 8,284,883 ordinary shares to cover over-allotments for 30 days.
The offering would increase shares outstanding from 43,662,403 as of March 31, 2026 to 98,894,961 ordinary shares immediately after the offering (or 107,179,844 if the underwriters exercise the full option). Net proceeds are allocated principally to U.S. commercialization, R&D for Genio system upgrades and manufacturability, international commercialization, clinical data and general corporate purposes.